It is reasonable to assume that the typically high density of CCK2 receptor expression on MTC lesions will enable successful implementation of targeted radionuclide therapy, as recently demonstrated in a limited patient set [27]; further clinical studies with emerging CCK2 receptor ligands are warranted [33, 38]. The gene discussed is CCKBR; the disease is medullary thyroid gland carcinoma.